Verteporfin photodynamic therapy combined with Bevacizumab therapy in neovascular secondary to central exuda-tive chorioretinopthy

Abstract:

AIM:To investigate the therapeutic effect of photo-dynamic therapy (PDT) combined with bevacizumab on central exudative chorioretinopthy(CEC). ·METHODS:Clinical data of 40 patients who had undergone PDT combined with bevacizumab because of choroidal neovascularisation caused by CEC,diagnosed by examination of best-corrected visual acuity (BCVA),ocular fundus fluorescein angiography (FFA),and optical coherence tomography (OCT),were retrospectively an-alyzed. The changes of the BCVA,ocular fundus charac-teristics,and the results of FFA and OCT before and after combined therapy were observed and analyzed. The numeration of the times of retreatment and the safety of the combination therapy were analyzed. ·RESULTS:At the end of the follow-up period after combination therapy,the BCVA improved more than 2 lines in 34 eyes,stabled in 5 eyes,lost more than 2 lines in 1 eye. ·CONCLUSION:PDT combined with bevacizumab the-rapy is an effective and safety therapy for most patients with CEC.

Key words:combination therapy;choroidal neovascularization;central exudative chorioretinopthy;clinical observation